Are certain patients more susceptible to tigecycline's liver impact?

Are some patients more likely to see liver enzyme changes with tigecycline?

Patients who already have mild liver impairment show higher tigecycline exposure than those with normal liver function. This has observed in pharmacokinetic studies where AUC increased by 25 percent in mild hepatic impairment and 55 percent in moderate impairment.

Does this mean tigecycline needs a dose adjustment for liver issues?

Current prescribing information does not recommend dose changes for patients with mild to moderate liver impairment. For severe hepatic impairment, a 50 percent dose reduction is advised after the loading dose.

What other factors raise risk for liver enzyme rises?

Patients who stay on tigecycline longer than recommended, or who have concurrent use of other drugs that stress the liver, appear more likely to develop enzyme elevations. Clinical trials reported transaminase increases in 5 to 8 percent of patients overall.

When does patent protection end for tigecycline?

Tigecycline’s composition-of-matter patent expired in 2018. Generic versions entered the market shortly thereafter.